The Wistar Institute Joins OncLive’s Strategic Alliance Partnership

OncLive’s newest strategic partner is a unique research-focused cancer center that is driving cutting-edge discoveries in cancer biology and genetics.

Business Wire


OncLive® is pleased to announce that the Wistar Institute has joined its Strategic Alliance Partnership program.

By participating in the Strategic Alliance Partnership program, The Wistar Institute will have the opportunity to work with OncLiveto promote its research programs and initiatives, and the discoveries made by its scientists to the nationwide oncology community.

The Wistar Institute is a National Cancer Institute-designated cancer center that conducts basic research to understand the causes, treatment, and prevention of cancer. It is one of only seven NCI-designated cancer centers focused exclusively on laboratory research.

The Wistar Institute has been at the forefront of cancer research for decades, contributing discoveries and breakthroughs that have led to the identification of genes associated with breast, lung, and prostate cancer, and the development of monoclonal antibodies and other significant research technologies and tools.

Wistar Institute scientists are engaged in several exciting areas of cancer research, including the Gene Expression and Regulation program, which focuses on identifying genes and the genetic mechanisms involved in cancer; the Molecular and Cellular Oncogenesis program, which focuses on the underlying processes of normal and malignant cell growth and differentiation; and the Tumor Microenvironment and Metastasis program, which looks for answers to basic questions about the role played by surrounding cells in tumor development, growth, and spread.

Scientists at Wistar also conduct cancer biology research, with an emphasis on the role that genes, hormones, and naturally occurring tumor suppressors play in the growth of tumors, and translational research that can improve current medicine or foster the creation of new therapies.

Jack Lepping, president of the oncology division of Intellisphere, the publisher of OncLive, said, “Working with a pure research institute like Wistar is an exciting new opportunity for us. We look forward to partnering with the researchers in programs like The Wistar Institute Melanoma Research Center and supporting their efforts to foster collaboration between scientists, clinicians, and industry. We’re also proud to help raise awareness and support Wistar’s mission of training the next generation of scientific investigators in oncology.”

This year, more than 20 cancer centers and nursing schools have joined OncLive’s Strategic Alliance Partnership program.

To learn more about OncLive®, visit

About OncLive® is the official website for Intellisphere’s Oncology Specialty Group, which publishes Oncology & Biotech News, OncologyLive, Oncology Nursing News, and Contemporary Oncology. The mission of OncLive® and its family of publications is to provide oncology professionals with the resources and information they need in order to provide the best care for their patients. The Oncology Specialty Group is a division of Intellisphere, LLC, a leading provider of health care publishing, research, and education. To learn more, please visit

About the Wistar Institute

The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the country, Wistar has long held the prestigious Cancer Center designation from the National Cancer Institute. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. The Wistar Institute: Today’s Discoveries – Tomorrow’s Cures. On the Web at

For OncLive
Mike Gross, 267-932-8760 Ext. 310


View Comments (0)